Cardiovascular Risk in Patients with Moderate-to-Severe Psoriasis: A Systematic Synthesis of Observational Studies

Authors

  • Lourdes Elena Barreto Romero
  • Alain Cabrera Orive
  • Lisbeth Madelayne Andrade Pizarro
  • Sharon Salomé Yari Guamán
  • Juan Sebastian Rodas Orellana

Keywords:

psoriasis, cardiovascular risk, inflammation, comorbidity, prevention.

Abstract

Introduction: Psoriasis is a systemic inflammatory disease associated with a higher risk of cardiovascular complications.

Objective: To evaluate evidence on the relationship between psoriasis and cardiovascular risk, considering disease severity and confounding factors.

Methods: We conducted a systematic review of observational studies published from 2015 to 2025 in three databases. We included adult-population research addressing cardiovascular outcomes in patients with psoriasis, applying PRISMA criteria for screening and ROBINS-I for quality assessment.

Results: Of 1,267 initial records, 22 articles were selected. Findings indicated a higher prevalence of hypertension, obesity, and dyslipidemia in individuals with psoriasis, especially in moderate to severe presentations. Vascular involvement markers (non-calcified coronary plaques, arterial stiffness) were also observed, alongside an increased risk of coronary events. The methodological quality varied from low to moderate, reflecting heterogeneity in definitions and potential unadjusted confounding.

Conclusions: The evidence suggests that psoriasis, particularly in its more severe forms, is a relevant cardiovascular risk factor. These results underscore the value of a comprehensive approach and close monitoring of cardiometabolic comorbidities in this patient group.

Downloads

Download data is not yet available.

Published

2025-06-05

How to Cite

1.
Barreto Romero LE, Cabrera Orive A, Andrade Pizarro LM, Yari Guamán SS, Rodas Orellana JS. Cardiovascular Risk in Patients with Moderate-to-Severe Psoriasis: A Systematic Synthesis of Observational Studies. Rev Cubana Inv Bioméd [Internet]. 2025 Jun. 5 [cited 2025 Jul. 17];44. Available from: https://revibiomedica.sld.cu/index.php/ibi/article/view/3846